TxCell snapped up by SangamoUS gene editing expert Sangamo Therapeutics is set to acquire French biotech TxCell in an all-cash buyout of €72m on a debt- and cash-free basis. more ➔
Sobi in €387m orphan drug deal with Novi...Swedish Orphan Biovitrum AB (Sobi) has signed a €387 deal with Swiss drug developer Novimmune for a late stage antibody targeting a rare haematology disorder. more ➔
Novartis pays €945m for eczema programmeEuropean biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to €945m. The Swiss pharma giant aims to strengthen its commitment to … more ➔
IMI to spur on antibiotics research amidst...The Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago. more ➔
Roche granted breakthrough status for live...Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giant’s mAb combination therapy for liver cancer. more ➔
Epigenetic biomarkers predict immunotherap...UK biotech Oxford BioDynamics has presented data showing that the company’s blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. more ➔
Urovant launches US$150m IPOSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron. more ➔
Immunooncology: Genmab teams up with Immat...Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications. more ➔
Big Data: Tracking cancer risk genesUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk. more ➔
Lifecare floats on Oslo stock exchangeNorwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor. more ➔
